Colorectal Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Colorectal Cancer is a $334M Part D market in peak maturity, dominated by two oral small molecules capturing 88% of spend.
Key Trends
- LONSURF (trifluridine/tipiracil) and STIVARGA (regorafenib) duopoly reflects late-stage disease focus
- Bevacizumab biosimilars (MVASI, ZIRABEV, ALYMSYS) fragmenting VEGF-directed segment despite originators' LOE approach
- High clinical trial load (1,372 trials) signals active pipeline development beyond current standard-of-care agents
Career Verdict
Colorectal cancer is a stable, well-established market suitable for commercial and medical affairs roles, but with limited innovation upside—early-career professionals should consider oncology subsegments with stronger growth signals.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LONSURF (trifluridine and tipiracil) | Taiho Oncology | $176M | 53% | PEAK | Stable | 10.6yr |
| 2 | STIVARGA (regorafenib) | Bayer | $111M | 33% | PEAK | Stable | 6.1yr |
| 3 | MVASI (bevacizumab-awwb) | Amgen | $13M | 4% | PEAK | Stable | |
| 4 | AVASTIN (bevacizumab) | Roche | $12M | 4% | LOE_APPROACHING | Declining | |
| 5 | ZIRABEV (bevacizumab-bvzr) | Pfizer | $9M | 3% | PEAK | Stable |
Drug Class Breakdown
market standard, stable
multi-mechanism, stable
biosimilar fragmentation
legacy, declining
Career Outlook
StableColorectal cancer is a mature, well-capitalized market with predictable revenue, stable competitor positions, and ongoing clinical trial activity supporting R&D and operations employment. The dominance of two oral agents and lack of imminent blockbuster approvals limit upside, but the indication's established treatment guidelines and high patient volume (third-leading cancer) ensure consistent commercial demand. Career progression is most attractive in commercial leadership, medical affairs strategy, and clinical operations roles within large diversified oncology portfolios.
Breaking In
Entry-level professionals should target commercial (sales rep) or clinical operations roles at large oncology employers (J&J, Takeda, Roche) to build established-market acumen; colorectal cancer's stability makes it ideal for learning sales execution without pipeline uncertainty.
For Experienced Professionals
Experienced professionals should pursue medical affairs, product strategy, or clinical development roles to drive lifecycle extensions (combination trials, new patient populations) or transition to emerging oncology areas; staying too long in a mature, duopolistic segment risks skill stagnation.
In-Demand Skills
Best For
Hiring Landscape
Colorectal cancer specialization spans 8,589 jobs across 15 companies, but hiring is concentrated in large, diversified oncology employers (Johnson & Johnson, Takeda, AbbVie, AstraZeneca) rather than pure colorectal-focused boutiques. Commercial roles dominate (1,675 jobs, $225K avg), followed by engineering (710 jobs, outlier $2.375M avg) and medical affairs (264 jobs, $302K avg), indicating strong demand for sales, medical science liaisons, and technical product specialists.
Top Hiring Companies
By Department
Commercial and medical affairs roles offer stable, well-paid positions with large employers, but engineering outlier suggests demand for specialized manufacturing/analytics roles; hiring is steady rather than explosive.
On Market (7)
Approved therapies currently available
Competitive Landscape
161 companies ranked by most advanced pipeline stage
+131 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 28,784 patients across 50 trials
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy
Radial Reload Laparoscopic LAR Case Series
A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Study in Second Line Metastatic Colorectal Cancer
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Related Jobs in Oncology
Medical Specialist II- Ophthalmology- Columbus
Medical Specialist II
Customer Service Representative
Sr. Account Manager - Molecular Instruments
Area Sales Manager
Data & AI Product Owner – Quality
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.